Ciclosporin ophthalmic - Santen

Drug Profile

Ciclosporin ophthalmic - Santen

Alternative Names: Cyclosporin modified ophthalmic - Santen; Cyclosporin ophthalmic - Santen; DE 076; PAPILOCK Mini ophthalmic solution 0.1%; Sanciclo

Latest Information Update: 10 Feb 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Cytokine inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Seasonal allergic rhinitis

Highest Development Phases

  • Marketed Seasonal allergic rhinitis

Most Recent Events

  • 23 Jan 2006 First global launch of ciclosporin ophthalmic
  • 23 Jan 2006 Launched for Seasonal allergic rhinitis in Japan (Ophthalmic)
  • 11 Oct 2005 Registered for Seasonal allergic rhinitis in Japan (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top